Chris Simon/LinkedIn
Mar 6, 2026, 15:09
Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis
Chris Simon, President and Chief Executive Officer at Haemonetics, Member of Board of Directors at Sotera Health Company and AdvaMed, shared on LinkedIn:
”Excited to receive FDA clearance for Persona PLUS, our proprietary, patent‑protected plasma apheresis technology.
This next‑generation, donor‑centric innovation advances the NexSys PCS platform, designed to safely improve yield, speed, and donor satisfaction.
Persona PLUS is supported by data from a randomized clinical trial with 30,000 plus donations from approximately 3,000 donors and was developed with our customers for the benefit of patients worldwide, with a clear focus on IgG yield and lowering cost per gram.”
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 07:41Global Study Defines ISTH BAT Reference Ranges in Children and Adolescents – JTH
-
Sep 13, 2026, 07:1010 Posts Not to Miss This Week
-
Sep 13, 2026, 07:04Mohamed Abdelhadi: Sharing Our Latest Publication
-
Sep 13, 2026, 05:36Speaking Up When Women’s Health Concerns Are Dismissed – Haemophilia Foundation Australia
-
Sep 13, 2026, 05:16W. Alberto Sifuentes Giraldo: Dual Targeted Therapy Shows Promise in Refractory Systemic Autoinflammatory Diseases
-
Sep 13, 2026, 04:42Christopher Robinson: Early Pregnancy Oxylipins May Signal Risk of Fetal Growth Restriction
-
Sep 13, 2026, 04:22Gabriela Hobbs: 2026 Society of Hematologic Oncology Meeting
-
Sep 13, 2026, 03:40Mizinga Moonze: When Blood Speaks – The Missing Link in Healthcare Sustainability
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research